Skip to main content
TipRanks
Go Ultimate75% OFF

Globus Medical (GMED) Q3 2026 Earnings Report

0 Followers

MX:GMED Q3 2026 EPS Results

Actual EPS
MXN 22.88
Consensus EPS
MXN 22.26
Beat/Miss
Beat by +MXN 0.61
One Year Ago EPS
MXN 21.95

MX:GMED Q3 2026 Revenue Results

Actual Revenue
MXN 14.21B
Expected Revenue
MXN 14.74B
Beat/Miss
Missed by -MXN 533.26M
YoY Revenue Growth
-0.69%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
MX:GMED Upcoming Earnings

Globus Medical's next earnings date is estimated for February 23, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

MX:GMED Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:0.00%|
Earnings Call Sentiment|Positive

The call was broadly constructive, supported by record free cash flow, expanding margins, strong Trauma and Enabling Technologies growth, continued product launches and maintained EPS guidance. However, near-term performance is being constrained by the 25.7% Nevro revenue decline, delayed Spine launches, weaker competitive recruiting, international softness and a reduction in 2026 revenue guidance. Management remained confident in the longer-term trajectory, particularly for 2027.

Company Guidance

For full year 2026, Globus Medical adjusted revenue guidance downward to $3.09 billion, compared to previous guidance of $3.18 billion to $3.22 billion, implying growth over 2025 of 5.1%; non-GAAP fully diluted earnings per share guidance remains in the range of $4.95 to $5.05, implying growth over 2025 ranging from 24.4% to 26.9%. The company reiterated adjusted gross profit margin in the range of 69% to 70% in 2026, representing a 90 to 190 basis point improvement over 2025, and expects R&D expense to be in the range of 4.5% to 5% of net sales for this year. Q4 guidance implies a mid-single-digit decline, while the company is not guiding on '27, though it said mid- to high single digits is where it would like to be for revenue growth, with earnings outperforming top line growth; it is also not guiding to free cash flow.

  • Record Free Cash Flow and EPS GrowthThird-quarter revenue was $763.7 million, while non-GAAP diluted EPS was $1.23, growing 4.4% over the prior-year quarter. Free cash flow reached a record $225 million, growing 5%, and operating cash flow was $265 million, growing 6%, despite a 13% increase in capital expenditures.
  • Base Business Revenue GrowthBase business Globus revenue, excluding Nevro, totaled $690 million and grew 3% as reported and 3.2% on a constant-currency basis.
  • Gross Margin and EBITDA ExpansionAdjusted gross profit margin increased to 69.5% from 68.1% in the prior-year quarter, marking the eighth straight quarter of sequential adjusted gross margin expansion. Total company adjusted EBITDA margin increased to 34.3% from 32.8%, while year-to-date adjusted EBITDA margin was 34%, up 370 basis points.
  • Improved GAAP Gross MarginGAAP gross profit margin was 66.7%, compared with 64.2% in the prior-year quarter. The company attributed adjusted gross margin improvement primarily to manufacturing and supply-chain synergies and favorable sales mix, partially offset by increased freight costs.
  • Enabling Technologies GrowthEnabling Technologies revenue was $34.9 million, growing 24% year over year and 34% sequentially. Overall EGPS and eHub units deployed, including sold, leased and rented units, grew 73% year over year and 65% year to date. Kyle Kline also reported capital units up 45% year over year and 23% sequentially.
  • Trauma and Neuromonitoring MomentumThird-quarter Trauma revenue grew 19% year over year. Trauma and Neuromonitoring each achieved double-digit growth for the fifth consecutive quarter. Management expects Trauma to contribute incrementally more to consolidated growth each year going forward.
  • EGPS Warning Letter ClosedThe FDA notified Globus Medical that the July 2024 EGPS warning letter had been closed following corrective actions. Management stated that the letter concerned administrative tracking of complaint handling and was not a patient-safety issue.
  • Robotic and Navigation AdoptionMore than 145,000 robotic cases have been performed using EGPS to date. Management identified EGPS and eHub navigation as key drivers of implant revenue growth in 2027 and beyond.
  • New Spine Product PipelineThe SCRIPT line of patient-specific implants and rods is currently available and includes seven new 3D-printed interbody cages, patient-specific rods, and expandable, interfixated and static options across ALIF, XLIF and TLIF categories. The XLIF Prone Solution and two-blade retractor are expected to be available later in the quarter, while the EIQ product suite is in the final stages of introduction and is expected to be a meaningful revenue contributor in 2027 and beyond.
  • Positive Surgeon Interest in SCRIPTManagement reported significant surgeon excitement regarding SCRIPT. The company stated that SCRIPT qualifies under the DRG category for a custom-made anatomical designed interbody fusion device and that initial cases have been encouraging as Globus works to scale the product in 2027.
  • Nevro Profitability ImprovementAlthough Nevro revenue declined, adjusted EBITDA margins expanded 370 basis points, driven by gross margin expansion and a more disciplined approach to operating expenses. Nevro EBITDA margin was 19.9% in the third quarter and 17.9% year to date, up more than 1,000 basis points from the comparable year-to-date period.
  • Nevro Sales Rebuilding and HFX Elite LaunchGlobus substantially completed rehiring lost Nevro sales headcount and reported increased output from newly trained associates. The company plans to launch the HFX Elite IPG in the first half of 2027, introducing bolus therapy and expanded MRI labeling.
  • International Growth Excluding NevroExcluding Nevro, year-to-date international business growth was 11.6%, which management also characterized as approximately 12%.
  • Strong Cash Position and Share RepurchasesCash, cash equivalents and marketable securities were $871.2 million at September 30, 2026, compared with $629.1 million at December 31, 2025. Globus repurchased $142.9 million of stock, or 1.9 million shares, during the quarter and $279 million, or 3.5 million shares, year to date. The Board authorized an additional $500 million for the share repurchase program, with $110 million remaining under the existing authorization.
  • Maintained EPS and Margin OutlookThe company reiterated 2026 non-GAAP diluted EPS guidance of $4.95 to $5.05, implying growth of 24.4% to 26.9% over 2025. It also reiterated adjusted gross margin guidance of 69% to 70%, representing a 90 to 190 basis point improvement over 2025.
  • Continued Product Development InvestmentManagement stated that Globus is expanding its in-house product development capabilities and expects research and development dollars to increase over the next several quarters. R&D expense is expected to be 4.5% to 5% of net sales for 2026.
  • Cranial and Digital Innovation AcquisitionsGlobus completed the Higgs Boson acquisition to support digital innovation and a surgical intelligence layer focused on data, analytics and closed-loop outcome monitoring. It also acquired Synaptive assets to expand into cranial neurosurgery, a market management estimates includes approximately 2 million procedures annually.
  • Long-Term Growth StrategyManagement remains focused on above-market U.S. Spine growth through new products, capital attachments and competitive recruiting, while continuing organic innovation, dedicated sales-team development, technology tuck-ins and investment across the musculoskeletal and cranial markets.

MX:GMED Earnings History

MX:GMED earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 23, 20272026 (Q4)23.98-23.81――
Nov 05, 20262026 (Q3)22.2622.8821.954.24% (+0.93)
Aug 06, 20262026 (Q2)20.4424.921655.81% (+8.93)
May 07, 20262026 (Q1)17.1120.8312.6564.71% (+8.18)
Feb 24, 20262025 (Q4)21.0923.8115.6252.38% (+8.18)
Nov 06, 20252025 (Q3)14.5321.9515.4442.17% (+6.51)
Aug 07, 20252025 (Q2)14.0116.0013.9514.67% (+2.05)
May 08, 20252025 (Q1)13.8412.6513.39-5.56% (-0.74)
Feb 20, 20252024 (Q4)13.9115.6211.1640.00% (+4.46)
Nov 05, 20242024 (Q3)12.0315.4410.645.61% (+4.84)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed